395 related articles for article (PubMed ID: 35668712)
21. Efficacy and Safety of Afatinib for EGFR-mutant Non-small Cell Lung Cancer, Compared with Gefitinib or Erlotinib.
Kim Y; Lee SH; Ahn JS; Ahn MJ; Park K; Sun JM
Cancer Res Treat; 2019 Apr; 51(2):502-509. PubMed ID: 29898592
[TBL] [Abstract][Full Text] [Related]
22. Comparing the effectiveness of different EGFR-TKIs in patients with EGFR mutant non-small-cell lung cancer: A retrospective cohort study in Taiwan.
Hsieh YY; Fang WT; Lo YW; Chen YH; Chien LN
Int J Cancer; 2020 Aug; 147(4):1107-1116. PubMed ID: 31854456
[TBL] [Abstract][Full Text] [Related]
23. Do patient characteristics affect EGFR tyrosine kinase inhibitor treatment outcomes? A network meta-analysis of real-world survival outcomes of East Asian patients with advanced non-small cell lung cancer treated with first-line EGFR-TKIs.
Chang HC; Wang CC; Tseng CC; Huang KT; Chen YM; Chang YP; Lai CH; Fang WF; Lin MC; Chuang HY
Thorac Cancer; 2023 Nov; 14(32):3208-3216. PubMed ID: 37737541
[TBL] [Abstract][Full Text] [Related]
24. Epidermal growth factor receptor tyrosine kinase inhibitors for de novo T790M mutation: A retrospective study of 44 patients.
Chang JW; Huang CY; Fang YF; Chang CF; Yang CT; Kuo CS; Hsu PC; Wu CE
Thorac Cancer; 2022 Jul; 13(13):1888-1897. PubMed ID: 35633141
[TBL] [Abstract][Full Text] [Related]
25. The Use of Cytotoxic Drugs as First Line Chemotherapy for EGFR (+) Nonsquamous NSCLC: A Network Meta-Analysis.
Li D; Li M; Li H; Shi P; Chen M; Yang T
Dis Markers; 2023; 2023():5272125. PubMed ID: 37077340
[TBL] [Abstract][Full Text] [Related]
26. Stepwise prolongation of overall survival from first to third generation EGFR-TKIs for EGFR mutation-positive non-small-cell lung cancer: the Tokushukai REAl-world Data project (TREAD 01).
Uryu K; Imamura Y; Shimoyama R; Mase T; Fujimura Y; Hayashi M; Ohtaki M; Otani K; Hibino M; Horiuchi S; Fukui T; Fukai R; Chihara Y; Iwase A; Yamada N; Tamura Y; Harada H; Shinozaki N; Tsuya A; Fukuoka M; Minami H
Jpn J Clin Oncol; 2024 Mar; 54(3):319-328. PubMed ID: 37997468
[TBL] [Abstract][Full Text] [Related]
27. Repeat biopsy procedures and T790M rates after afatinib, gefitinib, or erlotinib therapy in patients with lung cancer.
Lee K; Kim Y; Jung HA; Lee SH; Ahn JS; Ahn MJ; Park K; Choi YL; Sun JM
Lung Cancer; 2019 Apr; 130():87-92. PubMed ID: 30885357
[TBL] [Abstract][Full Text] [Related]
28. Overall survival in stage IV EGFR mutation‑positive NSCLC: Comparing first‑, second‑ and third‑generation EGFR‑TKIs (Review).
Vaid AK; Gupta A; Momi G
Int J Oncol; 2021 Feb; 58(2):171-184. PubMed ID: 33491758
[TBL] [Abstract][Full Text] [Related]
29. Monitoring of T790M in plasma ctDNA of advanced EGFR-mutant NSCLC patients on first- or second-generation tyrosine kinase inhibitors.
Huang CT; Lin CA; Su TJ; Yang CY; Tsai TH; Hsu CL; Liao WY; Chen KY; Ho CC; Yu CJ
BMC Cancer; 2023 Mar; 23(1):234. PubMed ID: 36915101
[TBL] [Abstract][Full Text] [Related]
30. Treatment outcomes of non-small cell lung cancers treated with EGFR tyrosine kinase inhibitors: a real-world cohort study.
Manninen O; Puuniemi L; Iivanainen S; Arffman M; Kaarteenaho R; Koivunen JP
Acta Oncol; 2023 Dec; 62(12):1854-1861. PubMed ID: 37934101
[TBL] [Abstract][Full Text] [Related]
31. Network meta-analysis of erlotinib, gefitinib, afatinib and icotinib in patients with advanced non-small-cell lung cancer harboring EGFR mutations.
Liang W; Wu X; Fang W; Zhao Y; Yang Y; Hu Z; Xue C; Zhang J; Zhang J; Ma Y; Zhou T; Yan Y; Hou X; Qin T; Dinglin X; Tian Y; Huang P; Huang Y; Zhao H; Zhang L
PLoS One; 2014; 9(2):e85245. PubMed ID: 24533047
[TBL] [Abstract][Full Text] [Related]
32. Real-world study of afatinib in first-line or re-challenge settings for patients with EGFR mutant non-small cell lung cancer.
Tanaka H; Taima K; Itoga M; Ishioka Y; Baba K; Shiratori T; Sakamoto H; Tsuchiya J; Nakagawa H; Hasegawa Y; Yasugahira H; Okudera K; Takanashi S; Tasaka S
Med Oncol; 2019 May; 36(6):57. PubMed ID: 31089973
[TBL] [Abstract][Full Text] [Related]
33. First-line treatment with irreversible tyrosine kinase inhibitors associated with longer OS in EGFR mutation-positive non-small cell lung cancer.
Su PL; Chen CW; Wu YL; Lin CC; Su WC
Thorac Cancer; 2021 Feb; 12(3):287-296. PubMed ID: 33336895
[TBL] [Abstract][Full Text] [Related]
34. Comparing survival and treatment response of patients with acquired T790M mutation second-line osimertinib versus sequential treatment of chemotherapy followed by osimertinib: A real-world study.
Wang CC; Lai CH; Chang YP; Chang HC; Tseng CC; Huang KT; Lin MC
Thorac Cancer; 2021 Dec; 12(23):3263-3272. PubMed ID: 34704378
[TBL] [Abstract][Full Text] [Related]
35. Network meta analysis of first-line therapy for advanced EGFR mutation positive non-small-cell lung cancer: updated overall survival.
Farris M; Larkin-Kaiser KA; Scory T; Boyne D; Wilner KD; Pastel M; Cappelleri JC; Ivanova JI
Future Oncol; 2020 Dec; 16(36):3107-3116. PubMed ID: 32869649
[No Abstract] [Full Text] [Related]
36. Real-world outcomes of first- and second-generation tyrosine kinase inhibitors first-line in patients with epidermal growth factor receptor mutation-positive non-small cell lung cancer: A retrospective observational cohort study.
Ng WW; Lin CC; Cheng CY; Jiang JS; Kao SJ; Yeh DY
PLoS One; 2021; 16(6):e0253335. PubMed ID: 34166400
[TBL] [Abstract][Full Text] [Related]
37. The Glasgow Prognostic Score Predicts Survival in Patients with Advanced Non-Small Cell Lung Cancer Harboring Sensitive Epidermal Growth Factor Receptor Mutations Who Are Treated with Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors.
Akazawa Y; Igawa S; Yamada K; Yamamoto H; Yagami Y; Kaizuka N; Manaka H; Kasajima M; Nakahara Y; Sato T; Mitsufuji H; Yokoba M; Kubota M; Sasaki J; Naoki K
Oncology; 2023; 101(11):685-694. PubMed ID: 37166346
[TBL] [Abstract][Full Text] [Related]
38. Cost-effectiveness of Osimertinib as First-line Treatment and Sequential Therapy for EGFR Mutation-positive Non-small Cell Lung Cancer in China.
Cai H; Zhang L; Li N; Chen S; Zheng B; Yang J; Weng L; Liu MB
Clin Ther; 2019 Feb; 41(2):280-290. PubMed ID: 30639208
[TBL] [Abstract][Full Text] [Related]
39. The Clinical Outcomes of Different First-Line EGFR-TKIs Plus Bevacizumab in Advanced EGFR-Mutant Lung Adenocarcinoma.
Huang YH; Hsu KH; Chin CS; Tseng JS; Yang TY; Chen KC; Su KY; Yu SL; Chen JJW; Chang GC
Cancer Res Treat; 2022 Apr; 54(2):434-444. PubMed ID: 34352999
[TBL] [Abstract][Full Text] [Related]
40. REPORT- Clinical outcomes of using second - versus first-Generation EGFR-tkis for the First-Line treatment of advanced NSCLC patients with EGFR mutations: A meta-analysis.
Hou B; Lu X; Gao DC; Liu QX; Zhou D; Zheng H; Dai JG
Pak J Pharm Sci; 2021 Jul; 34(4):1459-1468. PubMed ID: 34799322
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]